Page 255

Catalogue_WEB_WoP_Jun16

Pricing and Online Ordering at www.alphalabs.co.uk Clinical Chemistry Therapeutic Drug Monitoring Therapeutic drug monitoring (TDM) strategies are implemented on the assumption that clinical effects correlate better with drug concentrations in serum rather than with dose. TDM is often employed when using drugs with a narrow therapeutic window, where the concentrations producing the desired beneficial effects are relatively close to the concentrations which produce toxic results. Monitoring can also be beneficial in situations where drug toxicity is difficult to distinguish from underlying disease. Alpha offers a range of assays for monitoring anti-arrhythmia, anti-cancer, anti-epileptic and anti-inflammatory drugs. Digoxin Turbidimetric assay for the quantification of digoxin in human serum. Digoxin is used in the treatment of chronic heart failure, but in high doses it has toxic effects. Measuring Digoxin concentration at the start of treatment can confirm that a therapeutic dose is being achieved and interim monitoring can also be beneficial as changes to kidney function, thyroid problems, intestinal problems and cancer may all impact on circulating Digoxin levels. n Liquid-stable reagent, ready-to-use n Range: 0.25-5ng/ml n 6-point calibration curve Technical information: Latex particles coated with Digoxin are agglutinated when mixed with the Digoxin antibody solution. Digoxin in the patient sample competes with the latex particles slowing the process of agglutination. The absorbance change resulting from agglutination is inversely proportional to the amount of Digoxin in the patient sample. Digoxin Catalogue Number Description Pack Size A01405 Digoxin Turbidimetric Assay 2x8;2x6ml A12450 TDM Calibrator Set 6x3ml A09450 TDM Control Set 3x5ml DiaLab Methotrexate Sensitive enzyme immunoassay for the quantitative determination of methotrexate in serum or plasma. Methotrexate (MTX) is a cytotoxic drug which acts by competitively inhibiting dihydrofolate reductase (DHFR), the enzyme that converts folates to tetrahydrofolate. Disruption of DNA synthesis and 7-OH MTX metabolism mean that MTX therapy has potential for serious toxicity and patients should be closely monitored to enable prompt detection of toxic effects. Leucovorin (also known as folinic acid) is a synthetic substrate for DHFR and is frequently used in conjunction with MTX as a rescue therapy as it enables resumption of DNA synthesis in normal cells. Clinical guidelines typically recommend intravenous administration of leucovorin until MTX concentration fall below 0.05µmol/L. n Dual liquid-stable reagent n Does not react with 7-OH Mtx n Measuring range 0.05-1.00 µmol/L Technical information: Methotrexate in the patient sample competes with glucose- 6-phosphate dehydrogenase (G6PDH) labelled methotrexate to bind the antibody reagent. Binding of the labelled MTX reduces enzyme activity and therefore the rate of NAD to NADH conversion. Methotrexate Catalogue Number Description Pack Size 5026-0001-00 Methotrexate Assay 1x16ml, 1x8ml 5026-0002-00 Methotrexate Calibrator 6x2ml 5026-0003-00 Methotrexate Control Set 6x2ml 5026-0003-01 Methotrexate Normal Controls 3x2ml 5026-0003-02 Methotrexate High Range Controls 3x2ml 5026-0004-00 Methotrexate Dilution Buffer 1x25ml ARK Diagnostics Clinical Chemistry - Therapeutic Drug Monitoring n email order sales@alphalabs.co.uk n freefax order 0800 614249 253


Catalogue_WEB_WoP_Jun16
To see the actual publication please follow the link above